NIA Releases R21 RFA for Secondary Analyses of Comparative Effectiveness, Health Outcomes and Costs
The National Institute on Aging has released a Request for Applications (RFA) for Secondary Analyses of Comparative Effectiveness, Health Outcomes and Costs in Persons with Multiple Chronic Conditions (R21). The purpose of the RFA includes understanding the impact of specific combinations of chronic conditions in older persons on health, cost of care, and treatment interactions and comparative effectiveness. There is also room for key methodological work.
The National Institute on Aging has released a Request for Applications (RFA) for Secondary Analyses of Comparative Effectiveness, Health Outcomes and Costs in Persons with Multiple Chronic Conditions (R21). The purpose of the RFA includes understanding the impact of specific combinations of chronic conditions in older persons on health, cost of care, and treatment interactions and comparative effectiveness. There is also room for key methodological work. The web link and full purpose are listed below:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-003.html
Secondary Analyses of Comparative Effectiveness, Health Outcomes and Costs in Persons with Multiple Chronic Conditions (R21)
The National Institute on Aging (NIA) invites applications for short-term projects involving secondary analysis aimed at the following goals:
To assess the public health and health cost impact of specific combinations of two or more conditions in defined older populations, To identify potential differences in effectiveness and safety of different treatment regimens for patients with specific combinations of two or more conditions, To examine alterations in safety or effectiveness of a treatment for one condition related to the presence of one or more specific coexisting condition.
To identify and address methodological issues relevant to analyses of the health impact of multiple chronic conditions such as validity of data and confounding by indication.
Any questions can go to Dr. Marcel Salive, at 301-496-6761 or marcel.salive@nih.gov.
